Generics and Patent Strategies 2014 is a conference that covers topics such as:
- The Impact of Asian markets on the European generics industry
- Challenges of API synthesis and new EU Bioequivalence guidelines
- Strategies around Ever-greening practices employed by innovator companies to stave off Generic Competition
- The outcome of AstraZeneca’s filing for a breach of patent surrounding their gastro-protective compound Omeprazole
- Changes in regulatory affairs in key global markets
Generics and Patent Strategies 2014 brings together:
- Managing Director
- Head of Regulatory affairs
- VP, Research
- VP, Clinical
- Principal Scientist
- Medical Affairs Director
- Legal Council
- Clinical Regulatory Strategy Manager
- Chief Scientific Officer
- Clinical Pharmacologist
- Brand Manager
- Medical Director
- Commercial Director
- Head of Pharmacology
- Chief Medical Officer
- VP Chemistry
- Head of Clinical Science
- Head Global Licensing
- Consultants
- Director of Medical Affairs
- Chief Executive Officer
- Associate Clinicians
- Business Development Directors
- Vice President